BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

Inhibiting BRD9 for HIF2A-low renal cancer

By Claire Quang, Staff Writer
October 27, 2021 5:07 PM UTC

DISEASE CATEGORY: Cancer

INDICATION: Renal cancer...

BCIQ Company Profiles

Fudan University

Shanghai Jiao Tong University School of Medicine

BCIQ Target Profiles

Bromodomain containing 9 (BRD9)

Endothelial PAS domain protein 1 (HIF2A) (HIF-2alpha) (EPAS1)

Fat mass and obesity associated (FTO)

BCIQ Company Profiles

Fudan University

Shanghai Jiao Tong University School of Medicine

BCIQ Target Profiles

Bromodomain containing 9 (BRD9)

Endothelial PAS domain protein 1 (HIF2A) (HIF-2alpha) (EPAS1)

Fat mass and obesity associated (FTO)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2025 BioCentury Inc. All Rights Reserved.
Copyright © 2025 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS